Mid-Atlantic Bio Therapeutics (MABT) is a pharmaceutical company based in Doylestown, PA, founded in 2011 with a mission to eradicate life-threatening infectious diseases using their proprietary therapy technology, IMT504. Specializing in immunotherapy for infectious diseases, MABT is actively developing next-generation COVID-19 vaccines and focusing on a medical breakthrough for Rabies treatment.
Led by a team of experienced professionals in infectious diseases, research, and business development, MABT is at the forefront of creating innovative treatment paradigms for viral diseases. With a focus on revolutionizing medical care through immunotherapy, MABT aims to address critical global health challenges and provide effective solutions for unmet medical needs.
Generated from the website